292 related articles for article (PubMed ID: 17383164)
21. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
23. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
24. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
25. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice.
Al-Abd AM; Hong KY; Song SC; Kuh HJ
J Control Release; 2010 Feb; 142(1):101-7. PubMed ID: 19819274
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model.
Hribaschek A; Ridwelski K; Pross M; Meyer F; Kuhn R; Halangk W; Boltze C; Lippert H
Oncol Rep; 2003; 10(6):1793-8. PubMed ID: 14534698
[TBL] [Abstract][Full Text] [Related]
28. Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Oman M; Tölli J; Naredi P; Hafström LO
Cancer Chemother Pharmacol; 2004 Sep; 54(3):213-8. PubMed ID: 15138707
[TBL] [Abstract][Full Text] [Related]
29. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
31. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
32. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
Nagai K; Nogami S; Egusa H; Konishi H
Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
[TBL] [Abstract][Full Text] [Related]
34. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
36. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
37. Intracavitary treatment of malignant ascitic carcinomatosis with oily anticancer agents in rats.
Kimura M; Konno T; Oda T; Maeda H; Miyauchi Y
Anticancer Res; 1993; 13(5A):1287-92. PubMed ID: 8239499
[TBL] [Abstract][Full Text] [Related]
38. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors.
Laginha KM; Verwoert S; Charrois GJ; Allen TM
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6944-9. PubMed ID: 16203786
[TBL] [Abstract][Full Text] [Related]
39. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy.
Lai PS; Lou PJ; Peng CL; Pai CL; Yen WN; Huang MY; Young TH; Shieh MJ
J Control Release; 2007 Sep; 122(1):39-46. PubMed ID: 17628166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
